Tags

Type your tag names separated by a space and hit enter

Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.

Abstract

In the original publication, Table 2 note was incorrectly published as "SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2".

Authors+Show Affiliations

Oakenhurst Medical Practice, Blackburn, UK.Diabetes Research Unit Cymru, Swansea University, Swansea, UK.Medicus Health Partners, Enfield, UK.University Hospitals Southampton NHS Foundation Trust, Southampton, UK.Department of Diabetes and Endocrinology, Division of Medicine, University College London, London, UK.Department of Diabetes, University Hospital Llandough, Llandough, UK.North Berwick Health Centre, North Berwick, UK.University Hospitals of Leicester NHS Trust, Leicester, UK.CODES (Community Diabetes Education and Support), Manchester University NHS Foundation Trust, Manchester, UK.Department of Metabolic Medicine/Chemical Pathology, Lister Hospital, Stevenage, UK.Obesity and Endocrinology Research, University of Liverpool, Liverpool, UK. J.P.H.Wilding@liverpool.ac.uk.

Pub Type(s)

Published Erratum

Language

eng

PubMed ID

31321747

Citation

Ali, Amar, et al. "Correction To: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence Into Practice." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 2019.
Ali A, Bain S, Hicks D, et al. Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. Diabetes Ther. 2019.
Ali, A., Bain, S., Hicks, D., Newland Jones, P., Patel, D. C., Evans, M., ... Wilding, J. (2019). Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, doi:10.1007/s13300-019-0670-y.
Ali A, et al. Correction To: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence Into Practice. Diabetes Ther. 2019 Jul 18; PubMed PMID: 31321747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice. AU - Ali,Amar, AU - Bain,Steve, AU - Hicks,Debbie, AU - Newland Jones,Phillip, AU - Patel,Dipesh C, AU - Evans,Marc, AU - Fernando,Kevin, AU - James,June, AU - Milne,Nicola, AU - Viljoen,Adie, AU - Wilding,John, AU - ,, Y1 - 2019/07/18/ PY - 2019/7/20/pubmed PY - 2019/7/20/medline PY - 2019/7/20/entrez JF - Diabetes therapy : research, treatment and education of diabetes and related disorders JO - Diabetes Ther N2 - In the original publication, Table 2 note was incorrectly published as "SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m2. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches < 45 mL/min/1.73 m2". SN - 1869-6953 UR - https://www.unboundmedicine.com/medline/citation/31321747/Correction_to:_SGLT2_Inhibitors:_Cardiovascular_Benefits_Beyond_HbA1c-Translating_Evidence_into_Practice L2 - https://dx.doi.org/10.1007/s13300-019-0670-y DB - PRIME DP - Unbound Medicine ER -